NewAmsterdam Pharma (NAMS) Other financing activities (2023 - 2026)

NewAmsterdam Pharma has reported Other financing activities for 4 years, with the latest figure at $10.4 million in Q1 2026.

• Quarterly Other financing activities rose 31.46% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.0 million (up 147.37% YoY) and the FY2025 annual result came in at $29.5 million, up 114.14% from the prior year.
• Other financing activities fell to $10.4 million in Q1 2026 per NAMS's latest filing, from $12.5 million in the prior quarter.
• Over five years, Other financing activities peaked at $12.5 million in Q4 2025 and troughed at $1000.0 in Q3 2023.
• A 4-year average of $5.7 million and a median of $5.6 million in 2025 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 3577.65% in 2025, down 26.49% in 2025.
• Over 4 years, Other financing activities stood at $1000.0 in 2023, then soared by 33900.0% to $340000.0 in 2024, then jumped by 3577.65% to $12.5 million in 2025, then retreated by 16.71% to $10.4 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $10.4 million, $12.5 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.